Baxter completes $3.8B sale of kidney care business (Vantive) to Carlyle-backed buyers; net proceeds ~$3.71B

BAXTER INTERNATIONAL INC

Sale closed Jan 31, 2025; net pre-tax cash proceeds of approximately $3.71B after working capital and debt adjustments.
Chris Toth, EVP and Group President Kidney Care, ceased as executive officer effective closing date.
Amendment to purchase agreement clarifies cash adjustment definitions, post-closing cash sweep mechanics, and excess withholding tax exposure.
Original aggregate purchase price of $3.80B in cash, subject to closing adjustments.

item 2.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Chris Toth

Executive Vice President and Group President, Kidney Care

BAX · BAXTER INTERNATIONAL INC

Effective: 2025-01-31
Filed: February 3, 2025, 6:59 PM ET

In accordance with the terms and conditions of the Purchase Agreement, effective as of the Closing Date, Chris Toth ceased serving as Executive Vice President and Group President, Kidney Care, and as an executive officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Toth departed as Executive Vice President and Group President, Kidney Care at BAXTER INTERNATIONAL INC.

Action: ceased
Role: Executive Vice President and Group President, Kidney Care

Exact text from the filing

In accordance with the terms and conditions of the Purchase Agreement, effective as of the Closing Date, Chris Toth ceased serving as Executive Vice President and Group President, Kidney Care, and as an executive officer of the Company.

View on SEC.gov

BAXTER INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001628280-25-003388

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.